Study of New Tablet Formulations and Suspension Formulation Compared to Current (1B) Formulation of BILR 355 BS in Healthy Male Volunteer Subjects

• Status: Completed
• Trial end date: 1969-12-31

Summary

1. To investigate the relative bioavailability (BA) of improved tablet formulation candidates to determine which formulation will be developed for use in late Phase II and Phase III clinical trials

2. To investigate the relative BA of the pediatric suspension, compared to the current 1B formulation

3. To investigate the bioequivalence (BE) of BILR 355 BS in two tablet strengths; three 25mg tablets vs. one 75 mg tablet, current 1B formulation

• Phase: Phase 1

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Ritonavir